Skip to main content

Table 2 Study sample split by alveolar volume

From: Prognostic value of alveolar volume in systolic heart failure: a prospective observational study

  Alveolar volume (% predicted)  
Characteristic <80 (n = 135) ≥80 (n = 125) P-value
Age, years 71 (66–77) 64 (55–71) <0.001
Male gender 109 (81) 98 (78) 0.648
BMI, kg/m2 26 (24–29) 26 (23–30) 1.000
Current smoker 21 (16) 29 (23) 0.157
NYHA class III-IV 57 (42) 27 (22) <0.001
LVEF, % 30 (25–38) 33 (25–40) 0.710
Cardiothoracic ratio >0.5 93 (69) 69 (55) 0.029
NT-ProBNP, pg/mL 1607 (811–3878) 982 (297–2141) 0.003
Hemoglobin, g/dL 13.6 (12.5–14.7) 13.7 (12.4–15.0) 0.552
Creatinine, mmol/L 105 (82–137) 97 (82–114) 0.139
FEV1, % predicted 78 (65–87) 99 (90–109) <0.001
DLCO, % predicted 66 (53–75) 76 (68–92) <0.001
COPD 42 (31) 23 (18) 0.022
Ventilatory restriction 53 (39) 0 (0) <0.001
Coronary artery disease 66 (49) 49 (39) 0.134
Hypertension 75 (56) 66 (53) 0.709
Persistent atrial fibrillation 34 (25) 17 (14) 0.020
Prior stroke 10 (7) 11 (9) 0.821
Diabetes 44 (33) 38 (30) 0.790
Dyslipidemia 52 (39) 57 (44) 0.260
Beta-blockers 107 (79) 116 (93) 0.002
ACE-inhibitors 69 (51) 81 (65) 0.033
Angiotensin receptor antagonists 40 (30) 35 (28) 0.786
Loop diuretics 117 (87) 108 (86) 1.000
Potassium sparing drugs 84 (62) 91 (73) 0.085
Warfarin 28 (21) 14 (11) 0.043
Implanted pace-maker 20 (15) 15 (12) 0.589
Implanted defibrillator 5 (4) 8 (6) 0.398
  1. Data are numbers (%), or medians (interquartile range). For abbreviations see Table 1.